您当前所在的位置:首页 > 产品中心 > 产品信息
Clorazepate_分子结构_CAS_23887-31-2)
点击图片或这里关闭

Clorazepate

产品号 DB00628 公司名称 DrugBank
CAS号 23887-31-2 公司网站 http://www.ualberta.ca/
分子式 C16H11ClN2O3 电 话 (780) 492-3111
分子量 314.72314 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 510

产品价格信息

请登录

产品别名

标题
Clorazepate
IUPAC标准名
7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylic acid
IUPAC传统名
clorazepic acid
商标名
Novo-Clopate
Tranxene
Chlorazepic acid
Chlorazepate
Clorazepic acid
Clorazepate dipotassium
Clorazepic acid [BAN]
Gen-xene

产品登记号

PubChem CID 2809
CAS号 23887-31-2
PubChem SID 46506595

产品性质

疏水性(logP) 3
溶解度 Very soluble

产品详细信息

详细说明 (English)
Item Information
Drug Groups illicit; approved
Description A water-soluble benzodiazepine derivative effective in the treatment of anxiety. It has also muscle relaxant and anticonvulsant actions. [PubChem]
Indication For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal.
Pharmacology Clorazepate is a member of the group of drugs called benzodiazepines. Pharmacologically, clorazepate has the characteristics of the benzodiazepines. It has depressant effects on the central nervous system. The primary metabolite, nordiazepam, quickly appears in the blood stream. Studies in healthy men have shown that clorazenate has depressant effects on the central nervous system. Since orally administered clorazepate dipotassium is rapidly decarboxylated to form nordiazepam, there is essentially no circulating parent drug.
Toxicity Oral LD50 in rats is 1320 mg/kg. In monkeys, oral LD50 exceed 1600 mg/kg. Symptoms of overdose include confusion, coma, impaired coordination, sleepiness, and slowed reaction time.
Affected Organisms
Humans and other mammals
Biotransformation The drug is metabolized in the liver and excreted primarily in the urine. The primary metabolite, nordiazepam, is further metabolized by hydroxylation. The major urinary metabolite is conjugated oxazepam (3-hydroxynordiazepam), and smaller amounts of conjugated p-hydroxynordiazepam and nordiazepam are also found in the urine.
Absorption Rapidly absorbed following oral administration (bioavailability is 91%).
Half Life The serum half-life is about 2 days. Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours.
Protein Binding The protein binding of nordiazepam in plasma is high (97-98%).
Elimination The drug is metabolized in the liver and excreted primarily in the urine.
References
: Systematic review of the benzodiazepines. Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Committee on the Review of Medicines. Br Med J. 1980 Mar 29;280(6218):910-2. [Pubmed]
McElhatton PR: The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol. 1994 Nov-Dec;8(6):461-75. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

参考文献

  • : Systematic review of the benzodiazepines. Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Committee on the Review of Medicines. Br Med J. 1980 Mar 29;280(6218):910-2. Pubmed
  • McElhatton PR: The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol. 1994 Nov-Dec;8(6):461-75. Pubmed